Anemo Labs Raises £700K to Develop Disease Detection AI

The big picture: London-based deeptech startup Anemo Labs has raised £700,000 in pre-seed funding to develop its technology for detecting disease-related compounds through smell.

Why it matters:

• Non-invasive screening: Anemo Labs aims to enable early disease detection through the analysis of volatile organic compounds (VOCs) in urine, offering a non-invasive alternative to traditional diagnostic methods.
• Early intervention potential: The technology seeks to identify signs of disease, such as urinary tract infections and certain cancers, before symptoms manifest, potentially allowing for earlier clinical intervention.
• Continuous monitoring: Olfaction provides a passive and continuous medium for screening, offering a new paradigm for health monitoring beyond episodic check-ups.

How it works:

• Electronic nose technology: Anemo Labs develops ‘e-noses’ that combine specialized sensor hardware with advanced AI models to detect and classify VOCs, the molecules responsible for smell.
• Data-driven AI training: Central to its approach is an in-house sampling platform capable of collecting and labeling up to 5,000 smells per day, generating critical training data for its machine-learning models.
• Validated performance: Early testing using the Sniffin’ Sticks olfactory protocol demonstrated that Anemo’s models correctly classified scent categories 84.15% of the time across 12 categories.

The catch: While promising, the path to clinical adoption for AI-powered diagnostics is long and complex, requiring rigorous regulatory approval and extensive clinical validation beyond initial testing. Competing with established diagnostic methods and ensuring consistent accuracy across diverse patient populations and environmental factors will be critical challenges for Anemo Labs.